Analysis of the potential of cancer cell lines to release tissue factor-containing microvesicles: Correlation with tissue factor and PAR2 expression

被引：22
作者：
Ettelaie C. [1 ]
Collier M.E.W. [1 ,2 ]
Featherby S. [1 ]
Benelhaj N.E. [1 ,3 ]
Greenman J. [1 ]
Maraveyas A. [3 ]
机构：
[1] University of Hull, Biomedical Section, Department of Biological Sciences, Cottingham Road, Hull
[2] Glenfield General Hospital, Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Leicester
[3] University of Hull, Division of Cancer-Hull York Medical School, Cottingham Road, Hull
来源：
Thrombosis Journal | / 14卷 / 1期
关键词：
Blood coagulation; Cell line; Microvesicles; PAR; 2; Tissue factor;
D O I：
10.1186/s12959-016-0075-3
中图分类号：
学科分类号：
摘要：
Background: Despite the association of cancer-derived circulating tissue factor (TF)-containing microvesicles and hypercoagulable state, correlations with the incidence of thrombosis remain unclear. Methods: In this study the upregulation of TF release upon activation of various cancer cell lines, and the correlation with TF and PAR2 expression and/or activity was examined. Microvesicle release was induced by PAR2 activation in seventeen cell lines and released microvesicle density, microvesicle-associated TF activity, and phoshpatidylserine-mediated activity were measured. The time-course for TF release was monitored over 90 min in each cell line. In addition, TF mRNA expression, cellular TF protein and cell-surface TF activities were quantified. Moreover, the relative expression of PAR2 mRNA and cellular protein were analysed. Any correlations between the above parameters were examined by determining the Pearson's correlation coefficients. Results: TF release as microvesicles peaked between 30-60 min post-activation in the majority of cell lines tested. The magnitude of the maximal TF release positively correlated with TF mRNA (c = 0.717; p < 0.001) and PAR2 mRNA (c = 0.770; p < 0.001) expressions while the percentage increase correlated with PAR2 mRNA (c = 0.601; p = 0.011) and protein (c = 0.714; p < 0.001). There was only a weak correlation between resting TF release, and microvesicle release. However, TF release in resting cells did not significantly correlate with any of the parameters examined. Furthermore, TF mRNA expression correlated with PAR2 mRNA expression (c = 0.745; p < 0.001). Discussion and Conclusions: In conclusion, our data suggest that TF and PAR2 mRNA, and PAR2 protein are better indicators of the ability of cancer cells to release TF and may constitute more accurate predictors of risk of thrombosis. © 2016 Ettelaie et al.
引用
收藏
相关论文
共 57 条
[1]  
Khorana A.A., Cancer-associated thrombosis: updates and controversies, Hematol Am Soc Hematol Educ Program., 2012, pp. 626-630, (2012)
[2]  
Hu T., Bach R.R., Horton R., Konigsberg W.H., Todd M.B., Procoagulant activity in cancer cells is dependent on tissue factor expression, Oncol Res., 6, pp. 321-327, (1994)
[3]  
Cocco E., Varughese J., Buza N., Bellone S., Glasgow M., Bellone M., Et al., Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor, BMC Cancer, 11, (2011)
[4]  
Kothari H., Pendurthi U.R., Rao L.V., Analysis of tissue factor expression in various cell model systems: cryptic vs. active, J Thromb Haemost, 11, pp. 1353-1363, (2013)
[5]  
Thaler J., Preusser M., Ay C., Kaider A., Marosi C., Zielinski C., Pabinger I., Hainfellner J.A., Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients, Thromb Res., 131, pp. 162-165, (2013)
[6]  
Lwaleed B.A., Lam L., Lasebai M., Cooper A.J., Expression of tissue factor and tissue factor pathway inhibitor in microparticles and subcellular fractions of normal and malignant prostate cell lines, Blood Coagul Fibrinolysis, 24, pp. 339-343, (2013)
[7]  
Tormoen G.W., Cianchetti F.A., Bock P.E., McCarty O.J., Development of coagulation factor probes for the identification of procoagulant circulating tumor cells, Front Oncol., 2, (2012)
[8]  
Langer F., Spath B., Haubold K., Holstein K., Marx G., Wierecky J., Et al., Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation, Ann Hematol., 87, pp. 451-457, (2008)
[9]  
Haubold K., Rink M., Spath B., Friedrich M., Chun F.K., Marx G., Et al., Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer, Thromb Haemost., 101, pp. 1147-1155, (2009)
[10]  
Geddings J.E., Mackman N., Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients, Blood., 122, pp. 1873-1880, (2013)
123456